Lifordi Immunotherapeutics

Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026

The post Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026 appeared first on Lifordi Immunotherapeutics.

The post LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Has a Favorable Risk-Benefit Profile vs. Prednisone and Placebo in a First in Human Study appeared first on Lifordi Immunotherapeutics.

Dr. Lauren S. Baker founded Insight Medical Consulting in 2021 where she and her team are assisting companies with regulatory and clinical strategy work. Dr. Baker has a unique background that has leveraged her technical engineering background and strong

L. Mary Smith, Ph.D. is a biotechnology executive with nearly three decades of experience leading drug development and advancing innovative therapies across oncology, immunotherapy, gene therapy, and rare diseases. She currently serves as Chief Operating

Dr. Niti Goel is a board-certified rheumatologist with over 25 years of academic, preclinical to late-stage drug development, and medical affairs experience. She is Chief Medical Officer of HotSpot Therapeutics, Inc., as well as President and Co-founder o

Dr. Merkel is the Chief of Rheumatology and a Professor of Medicine and Epidemiology at the University of Pennsylvania. Dr. Merkel is an internationally recognized research and clinical expert in vasculitis, scleroderma, and other systemic autoimmune dise

Dr. Weinblatt is a board-certified Rheumatologist at Brigham & Women's Hospital in Boston, MA and has almost 50 years of experience. Dr. Weinblatt was the President of the American College of Rheumatology in 2001. Dr. Weinblatt is the author of The Arthri

Dr. Cohen is an adjunct professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and in private practice at Rheumatology Associates, Dallas, Texas. He is director of the Division of Rheumatology at Presbyteri